Loading...

ANAB ANAPTYSBIO INC Investments/Divestments 8-K Filing

NPTY

NB

ANAPTYSBIO INC

(ANAB)

2023 8-K

Legal Dispute Filed

Stock Repurchase Update

Legal Dispute Filing

Investor Update

Financial Results

Investor Presentation Update

Business Separation Plans

Product Expansion

Financial Statements

Stock Repurchase

Financial Results

Investor Presentation

Clinical Trial Results

License Agreement

Financial Results

Financial Results Announcement

Annual Meeting of Stockholders

Earnings Reports

Financial Results Announcement

Financial Information Prese...

License Agreement with Cent...

Earnings Report

Clinical Trial Results

Management Changes

Financial Results Announcement

Annual Meeting of Stockholders

Earnings Report

Resignation and Appointment...

Financial Results Announcement

Amendment to Bylaws

Stock Repurchase Plan

Financial Update

External Links:

AnaptysBio, Inc. entered into a License Agreement with Centessa Pharmaceuticals for the exclusive worldwide license of the BDCA2 modulator antibody portfolio for autoimmune and inflammatory diseases, with a one-time cash payment of $7 million and additional milestone payments and royalties.

AI Assistant

ANAPTYSBIO INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.